<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37502400</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>Screening of a new candidate coxsackievirus B1 vaccine strain based on its biological characteristics.</ArticleTitle><Pagination><StartPage>1172349</StartPage><MedlinePgn>1172349</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1172349</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2023.1172349</ELocationID><Abstract><AbstractText>Coxsackievirus B1 (CVB1) is one of the significant pathogens causing viral myocarditis, hand, foot, and mouth disease (HFMD), and aseptic meningitis, and it has been associated with type 1 diabetes (T1DM). No effective antiviral drugs against CVB1 infection or preventive vaccines are available. Due to the success of two inactivated vaccines against enterovirus 71 and poliovirus, an inactivated Vero cell-based CVB1 vaccine could be developed. In this study, we isolated a high-growth CVB1 virus strain KM7 in Vero cells and developed a Vero-adapted vaccine candidate strain KM7-X29 via three rounds of plaque purification and serial passages. The KM7-X29 strain was grouped into the GII sub-genotype, which belonged to the Chinese epidemic strain and grew to a titer of more than 10<sup>7</sup> CCID50/ml in Vero cells. The inactivated CVB1 vaccine produced by the KM7-X29 strain induced an effective neutralizing antibody response in BALB/c mice, and maternal antibodies were able to provide a 100% protective effect against lethal challenges with a CVB1 strain in suckling BALB/c mice. Thus, the KM7-X29 strain might be used as a new candidate coxsackievirus B1 vaccine strain. The neonatal murine model of CVB1 infection will contribute to the development of the CVB1 vaccine.</AbstractText><CopyrightInformation>Copyright © 2023 Zhang, Xu, Liu, Wang, Xu, Gao, Feng, Guo and Ma.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Danhan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Yuhan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lilan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Changzeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shaohui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Vero cell</Keyword><Keyword MajorTopicYN="N">coxsackievirus B1</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">murine model</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37502400</ArticleId><ArticleId IdType="pmc">PMC10369069</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2023.1172349</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beck M. A., Shi Q., Morris V. C., Levander O. A. (1995). Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat. Med. 1, 433–436. 10.1038/nm0595-433</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0595-433</ArticleId><ArticleId IdType="pubmed">7585090</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkoova B., Pospisilova M., Kramna L., Kissova R., Berakova K., Klement C., et al. . (2021). Coxsackievirus B4 sewage-isolate induces pancreatitis after oral infection of mice. FEMS Microbiol. Lett. 368, fnab092. 10.1093/femsle/fnab092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsle/fnab092</ArticleId><ArticleId IdType="pmc">PMC8346287</ArticleId><ArticleId IdType="pubmed">34297106</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) (2008). Increased detections and severe neonatal disease associated with coxsackievirus B1 infection–United States, 2007. MMWR Morb. Mortal. Wkly. Rep. 57, 553–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18496504</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Weng Y. W., Zhang Y. J., He W. X., Zhu Y., Yu T. T., et al. . (2019). Molecular Epidemiology of coxsackievirus B1-5 Associated with HFMD in Fujian Province, China, 2011-2016. Biomed. Environ. Sci. 32, 633–638. 10.3967/bes2019.082</Citation><ArticleIdList><ArticleId IdType="doi">10.3967/bes2019.082</ArticleId><ArticleId IdType="pubmed">31488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu P. Y., Tyan Y. C., Chen Y. S., Chen H. L., Lu P. L., Chen Y. H., et al. . (2015). Transmission and demographic dynamics of coxsackievirus B1. PLoS One. 10, e0129272. 10.1371/journal.pone.0129272</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129272</ArticleId><ArticleId IdType="pmc">PMC4460132</ArticleId><ArticleId IdType="pubmed">26053872</ArticleId></ArticleIdList></Reference><Reference><Citation>Green A., Hede S. M., Patterson C. C., Wild S. H., Imperatore G., Roglic G., et al. . (2021). Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 64, 2741–2750. 10.1007/s00125-021-05571-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05571-8</ArticleId><ArticleId IdType="pmc">PMC8563635</ArticleId><ArticleId IdType="pubmed">34599655</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan H., Wang J., Wang C., Yang M., Liu L., Yang G., et al. . (2015). Etiology of multiple non-ev71 and non-cva16 enteroviruses associated with hand, foot and mouth disease in Jinan, China, 2009-June 2013. PLoS One. 10, e0142733. 10.1371/journal.pone.0142733</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142733</ArticleId><ArticleId IdType="pmc">PMC4642993</ArticleId><ArticleId IdType="pubmed">26562154</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Xu D., Cong S., Du Z., Li L., Zhang M., et al. . (2022). Co-infection and enterovirus B: post EV-A71 mass vaccination scenario in China. BMC Infect. Dis. 22, 671. 10.1186/s12879-022-07661-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07661-3</ArticleId><ArticleId IdType="pmc">PMC9354358</ArticleId><ArticleId IdType="pubmed">35927711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi M. M., Stone V. M., Andrejeff T., Heinimäki S., Sioofy-Khojine A. B., Marjomäki V., et al. . (2019b). Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral. Res. 171, 104595. 10.1016/j.antiviral.2019.104595</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104595</ArticleId><ArticleId IdType="pubmed">31491431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi M. M., Stone V. M., Sioofy-Khojine A. B., Heinimäki S., Marjomäki V., Hyöty H., et al. . (2019a). A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine. 37, 5962–5971. 10.1016/j.vaccine.2019.08.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.08.037</ArticleId><ArticleId IdType="pubmed">31471148</ArticleId></ArticleIdList></Reference><Reference><Citation>Iizuka N., Kuge S., Nomoto A. (1987). Complete nucleotide sequence of the genome of coxsackievirus B1. Virology. 156, 64–73. 10.1016/0042-6822(87)90436-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(87)90436-3</ArticleId><ArticleId IdType="pubmed">3027969</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., Patel B., Bhatt G. C. (2014). Enteroviral encephalitis in children: clinical features, pathophysiology, and treatment advances. Pathog. Glob. Health. 108, 216–222. 10.1179/2047773214Y.0000000145</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/2047773214Y.0000000145</ArticleId><ArticleId IdType="pmc">PMC4153822</ArticleId><ArticleId IdType="pubmed">25175874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H., Fan H., Lu P. X., Zhang X. F., Ai J., Shi C., et al. . (2019). Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: epidemiology, etiology, and disease burden. BMC Infect. Dis. 19, 79. 10.1186/s12879-018-3659-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3659-7</ArticleId><ArticleId IdType="pmc">PMC6341624</ArticleId><ArticleId IdType="pubmed">30669973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersten G., Hazendonk T., Beuvery C. (1999). Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine. 17, 2059–2066. 10.1016/S0264-410X(98)00409-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(98)00409-5</ArticleId><ArticleId IdType="pubmed">10217607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Kang B., Hwang S., Hong J., Chung J., Kim S., et al. . (2013). Molecular characteristics of human coxsackievirus B1 infection in Korea, 2008–2009. J. Med. Virol. 85, 110–115. 10.1002/jmv.23359</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23359</ArticleId><ArticleId IdType="pubmed">23073968</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O. H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M. M., Huhtala H., et al. . (2014). Coxsackievirus B1 is associated with induction of β-cell autoimmunity that portends type 1 diabetes. Diabetes. 63, 446–455. 10.2337/db13-0619</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson P. G., Lakshmikanth T., Laitinen O. H., Utorova R., Jacobson S., Oikarinen M., et al. . (2015). A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia. 58, 346–354. 10.1007/s00125-014-3436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-014-3436-0</ArticleId><ArticleId IdType="pubmed">25370797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Yang J. H., Lee J. E., Kim Y. O. (2022). Serotype analysis of pediatric enteroviral meningitis in Gwangju, Republic of Korea: Number of annual cases, distribution by age group, and characteristics of each serotype. J. Clin. Virol. 153, 105192. 10.1016/j.jcv.2022.105192</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105192</ArticleId><ArticleId IdType="pubmed">35661584</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Zhang M., Feng C., Cong S., Xu D., Sun H., et al. . (2021). characterization of coxsackievirus a6 strains isolated from children with hand, foot, and mouth disease. Front. Cell Infect. Microbiol. 11, 700191. 10.3389/fcimb.2021.700191</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.700191</ArticleId><ArticleId IdType="pmc">PMC8418080</ArticleId><ArticleId IdType="pubmed">34490141</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhu Y., Pan Y., Liu Z., Guo C., Ma S. (2015). Complete genome sequence analysis of two human coxsackievirus A9 strains isolated in Yunnan, China, in 2009. Virus Genes. 50, 358–364. 10.1007/s11262-015-1180-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-015-1180-2</ArticleId><ArticleId IdType="pubmed">25680342</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P., Yuan Y., Cui B., Huo Y., Bian L., Chen L., et al. . (2021). Cross-antigenicity between EV71 Sub-genotypes: implications for vaccine efficacy. Viruses. 13, 720. 10.3390/v13050720</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050720</ArticleId><ArticleId IdType="pmc">PMC8143144</ArticleId><ArticleId IdType="pubmed">33919184</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P. C. (2012). Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr. Opin. Virol. 2, 199–205. 10.1016/j.coviro.2012.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.02.009</ArticleId><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasri D., Bouslama L., Pillet S., Bourlet T., Aouni M., Pozzetto B. (2007). Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert. Rev. Mol. Diagn. 7, 419–434. 10.1586/14737159.7.4.419</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.7.4.419</ArticleId><ArticleId IdType="pubmed">17620049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndiaye N., Thiaw F. D., Fall A., Kébé O, Diatta K. L., Dia N., et al. . (2022). Molecular epidemiology of enterovirus a71 in surveillance of acute flaccid paralysis cases in Senegal, 2013-2020. Vaccines (Basel). 10, 843. 10.3390/vaccines10060843</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060843</ArticleId><ArticleId IdType="pmc">PMC9230434</ArticleId><ArticleId IdType="pubmed">35746451</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M. S., Maher K., Kilpatrick D. R., Pallansch M. A. (1999). Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J. Virol. 73, 1941–1948. 10.1128/JVI.73.3.1941-1948.1999</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.3.1941-1948.1999</ArticleId><ArticleId IdType="pmc">PMC104435</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S., Tauriainen S., Hober D., Lucas B., Vazeou A., Sioofy-Khojine A., et al. . (2014). Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes. 63, 655–662. 10.2337/db13-0620</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0620</ArticleId><ArticleId IdType="pubmed">24009257</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S. S., Wei Z. N., Jin W. P., Wu J., Zhou Y. P., Meng S. L., et al. . (2021). Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model. Emerg. Microbes. Infect. 10, 763–773. 10.1080/22221751.2021.1906755</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1906755</ArticleId><ArticleId IdType="pmc">PMC8079124</ArticleId><ArticleId IdType="pubmed">33739899</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn K. K., Wollersheim S. K., Krogstad P. (2014). Complete genome sequence of coxsackievirus b1 isolated during case outbreaks in 2007 in the United States. Genome Announc. 2, e00574–e00514. 10.1128/genomeA.00574-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/genomeA.00574-14</ArticleId><ArticleId IdType="pmc">PMC4110215</ArticleId><ArticleId IdType="pubmed">25059857</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed Z., Cardosa M. J. (2016). Status of research and development of vaccines for enterovirus 71. Vaccine. 34, 2967–2970. 10.1016/j.vaccine.2016.02.077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.077</ArticleId><ArticleId IdType="pubmed">26973065</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H. (2016). Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 34, 1975–1985. 10.1016/j.vaccine.2014.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.11.015</ArticleId><ArticleId IdType="pubmed">25448090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine A. B., Lehtonen J., Nurminen N., Laitinen O. H., Oikarinen S., Huhtala H., et al. . (2018). Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia. 61, 1193–1202. 10.1007/s00125-018-4561-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4561-y</ArticleId><ArticleId IdType="pubmed">29404673</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V. M., Hankaniemi M. M., Laitinen O. H., Sioofy-Khojine A. B., Lin A., Diaz Lozano I. M., et al. . (2020). A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv. 6, eaaz2433. 10.1126/sciadv.aaz2433</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V. M., Hankaniemi M. M., Svedin E., Sioofy-Khojine A., Oikarinen S., Hyöty H., et al. . (2018). A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 61, 476–481. 10.1007/s00125-017-4492-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4492-z</ArticleId><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Nikolova I., Galabov A. S. (2015b). Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice. Antiviral Res. 121:138–144. 10.1016/j.antiviral.2015.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.07.004</ArticleId><ArticleId IdType="pubmed">26196747</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Nikolova I., Pürstinger G., Dobrikov G., Dimitrov V., Philipov S., et al. . (2015a). Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice. Antivir. Chem. Chemother. 24(5–6):136–47. 10.1177/2040206616671571</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206616671571</ArticleId><ArticleId IdType="pmc">PMC5890508</ArticleId><ArticleId IdType="pubmed">27815331</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma N. A., Zheng X. T., Harris M. U., Cadichon S. B., Melin-Aldana H., Khetsuriani N., et al. . (2009). Outbreak of life-threatening coxsackievirus B1 myocarditis in neonates. Clin. Infect. Dis. 49, 759–763. 10.1086/605089</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/605089</ArticleId><ArticleId IdType="pubmed">19622042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. H., Wang A., Liu P. P., Zhang W. Y., Du J., Xu S., et al. . (2018). Divergent pathogenic properties of circulating coxsackievirus a6 associated with emerging hand, foot, and mouth disease. J. Virol. 92, e00303–e00318. 10.1128/JVI.00303-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00303-18</ArticleId><ArticleId IdType="pmc">PMC5952127</ArticleId><ArticleId IdType="pubmed">29563294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Liu C. C., Yang Y. J., Yang H. B., Lin C. H., Wang J. R. (1998). Fatal coxsackievirus B infection in early infancy characterized by fulminant hepatitis. J. Infect. 37, 270–273. 10.1016/S0163-4453(98)92076-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-4453(98)92076-X</ArticleId><ArticleId IdType="pubmed">9892531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikswo M. E., Khetsuriani N., Fowlkes A. L., Zheng X., Peñaranda S., Verma N., et al. . (2009). Increased activity of Coxsackievirus B1 strains associated with severe disease among young infants in the United States, 2007-2008. Clin. Infect. Dis. 49, e44–51. 10.1086/605090</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/605090</ArticleId><ArticleId IdType="pubmed">19622041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S. N., Tam A. Y., Ng T. H., Ng W. F., Tong C. Y., Tang T. S. (1989). Fatal Coxsackie B1 virus infection in neonates. Pediatr. Infect Dis. J. 8, 638–641. 10.1097/00006454-198909000-00015</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-198909000-00015</ArticleId><ArticleId IdType="pubmed">2552390</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Wu Y., Zhu R., Xu L., Lin Y., Yang H., et al. . (2021). Development of A neonatal mouse model for coxsackievirus b1 antiviral evaluation. Virol Sin. 36, 1575–1584. 10.1007/s12250-021-00444-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-021-00444-1</ArticleId><ArticleId IdType="pmc">PMC8476979</ArticleId><ArticleId IdType="pubmed">34581960</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>